MWNA
CSTL icon

Marshall Wace North America’s Castle Biosciences CSTL Stock Holding History

Marshall Wace North America’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-8,650
Closed -$445K – 1353
2020
Q3 		$445K Sell
8,650
-52,238
-86% -$2.32M ﹤0.01% 989
2020
Q2 		$2.29M Buy
60,888
+53,290
+701% +$1.82M 0.02% 554
2020
Q1 		$227K Buy
+7,598
New +$229K ﹤0.01% 878
2019
Q4 		– Sell
-24,524
Closed -$444K – 1333
2019
Q3 		$444K Buy
+24,524
New +$544K ﹤0.01% 833

Other funds holding CSTL

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace North America's CSTL Position: Q4 2020 in Review

Marshall Wace North America sold out of Castle Biosciences (CSTL) in Q4 2020, closing a stake of 8,650 shares — an estimated $445K sold.

Marshall Wace North America first reported a position in CSTL in Q3 2019 and held it in 4 quarters. The position peaked at $2.29M in Q2 2020. 163 funds tracked by Wall St. Rank hold CSTL as of Q4 2020.

  • Marshall Wace North America reported no remaining Castle Biosciences position as of Q4 2020 after selling out during the quarter.
  • Marshall Wace North America sold 8,650 Castle Biosciences shares in Q4 2020, an estimated $445K.
  • Marshall Wace North America first reported a position in Castle Biosciences in Q3 2019 and held it in 4 quarters.
  • Marshall Wace North America's Castle Biosciences position peaked at $2.29M in Q2 2020.
  • 163 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.